Cyclacel Pharmaceuticals : January 2022 Corporate Presentation

Published: 2022-01-21 11:03:31 ET CYCC

Translating cancer biology into medicines

Corporate Presentation January 2022

Disclaimer

This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward- looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling patients, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Cyclacel Summary

Experienced Executive Leadership

Spiro Rombotis

President & CEO

Paul McBarron

COO & CFO

Mark Kirschbaum, MD

CMO

STERLING DRUG

New Therapeutic Strategy: Degrade Cancer Escape Mechanisms

We need well tolerated, orally available, precision medicines to:

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Cyclacel Pharmaceuticals Inc. published this content on 21 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 January 2022 16:02:01 UTC.